Cwm LLC Has $69,000 Position in CryoPort, Inc. (NASDAQ:CYRX)

Cwm LLC increased its stake in shares of CryoPort, Inc. (NASDAQ:CYRX) by 1,437.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 11,328 shares of the company’s stock after buying an additional 10,591 shares during the period. Cwm LLC’s holdings in CryoPort were worth $69,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Franklin Resources Inc. lifted its position in CryoPort by 0.4% during the fourth quarter. Franklin Resources Inc. now owns 387,131 shares of the company’s stock worth $3,012,000 after acquiring an additional 1,512 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. increased its stake in shares of CryoPort by 148.7% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock worth $28,000 after purchasing an additional 2,120 shares during the period. Nebula Research & Development LLC increased its stake in shares of CryoPort by 21.6% during the fourth quarter. Nebula Research & Development LLC now owns 12,442 shares of the company’s stock worth $97,000 after purchasing an additional 2,207 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in CryoPort by 8.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 60,003 shares of the company’s stock worth $467,000 after purchasing an additional 4,902 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in CryoPort by 11.6% in the 4th quarter. Invesco Ltd. now owns 51,803 shares of the company’s stock valued at $403,000 after purchasing an additional 5,364 shares during the period. Institutional investors own 92.90% of the company’s stock.

Insiders Place Their Bets

In other news, insider Edward J. Zecchini sold 51,500 shares of CryoPort stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $6.84, for a total value of $352,260.00. Following the transaction, the insider owned 90,411 shares in the company, valued at approximately $618,411.24. This trade represents a 36.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Jerrell Shelton sold 16,344 shares of the company’s stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $7.06, for a total value of $115,388.64. Following the sale, the chief executive officer owned 912,419 shares of the company’s stock, valued at approximately $6,441,678.14. This represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 490,447 shares of company stock valued at $3,337,198 over the last ninety days. Company insiders own 10.00% of the company’s stock.

CryoPort Trading Down 0.8%

Shares of CryoPort stock opened at $7.27 on Friday. The company has a quick ratio of 5.24, a current ratio of 5.56 and a debt-to-equity ratio of 0.51. CryoPort, Inc. has a 12-month low of $4.58 and a 12-month high of $9.66. The company has a market capitalization of $364.52 million, a price-to-earnings ratio of -3.11 and a beta of 1.88. The firm’s 50-day moving average price is $7.03 and its two-hundred day moving average price is $6.59.

CryoPort (NASDAQ:CYRX) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. The company had revenue of $41.04 million during the quarter, compared to the consensus estimate of $56.19 million. CryoPort had a negative net margin of 50.15% and a negative return on equity of 11.03%. On average, analysts forecast that CryoPort, Inc. will post -0.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on CYRX shares. Stephens assumed coverage on CryoPort in a report on Tuesday, July 22nd. They issued an “overweight” rating and a $13.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and issued a $11.00 price target on shares of CryoPort in a research note on Thursday, May 8th. BTIG Research dropped their price objective on shares of CryoPort from $13.00 to $10.00 and set a “buy” rating for the company in a research note on Monday, July 7th. Guggenheim reissued a “buy” rating and issued a $10.00 price objective on shares of CryoPort in a report on Wednesday, April 16th. Finally, Morgan Stanley lowered their target price on shares of CryoPort from $8.00 to $7.00 and set an “equal weight” rating on the stock in a report on Monday, May 5th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $10.63.

About CryoPort

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.